A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
We are testing the hypothesis that subjects in the treatment group will experience fewer
fasting induced headaches as compared to those in the placebo group.In our clinical
experience, we estimate that approximately 25% of our headache population experiences
fasting-induced migraine or hunger-induced migraine. With a given migraine incidence of 28
million in the United States alone, we estimate that approximately 7 million will experience
hunger as a migraine trigger. If an individual has a known migraine trigger, then there are a
variety of ways to modify care in order to address that trigger. The simplest is to avoid
that trigger or preemptively treat that trigger. Frovatriptan has good evidence for daily use
for a short time to help prevent menstrually related migraines. A short course of treatment
can often avoid the initiation of the migraine and improve quality of life. Knowing that a
longer acting triptan, such as frovatriptan, has demonstrated capability at suppressing
headache through a known trigger, suggests the need to study this with fasting induced
migraines, as well.